MedTrace Logo

Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX

NCT06723990 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-02-11

No results posted yet for this study

Summary

To prospectively evaluate the impact of HER2DX on the decision-making processes of the treating physicians and especially among the routine multidisciplinary tumour board, in defining type and setting of systemic therapy administration in patients with stage I-III HER2+ BC, and the degree of clinician's confidence in the treatment recommendation.

Conditions

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

DRUG

Neoadjuvant standard treatment for HER2+

NEOADJUVANT SETTING

DRUG

Adjuvant standard treatment for HER2+

ADJUVANT SETTING

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Paola Zagami · Istituto Europeo di Oncologia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2027-11-30
Completion
2027-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06723990 on ClinicalTrials.gov